In recent decades, the biology of aging has ceased to be a speculative field to become one of the most dynamic areas of biomedical research. Far from limiting itself to prolonging life, current science is aiming for a more ambitious goal: reversing the aging process itself. Building on milestones such as cellular reprogramming and the elimination of senescent cells, researchers around the world are now exploring the molecular mechanisms that determine biological age, opening up the possibility of regenerative medicine capable of not only adding years to life, but life to years.

In search of aging reversal

Mephistopheles, using the powers conferred upon him by his demonic nature, granted Faust renewed youth. Curiously, what Goethe immortalized in literature as a myth—the recovery of youth—is emerging today as an increasingly plausible goal for the advancement of scientific research.

The focus is no longer simply on continuing the progressive lengthening of lifespans we have experienced over the past 150 years. During this time, advances in medicine and public health have significantly increased average life expectancy, but this longevity has come with a tradeoff: age-related diseases have become more prevalent and difficult to treat.

Faced with this challenge, a deep understanding of the molecular causes of decline has given rise to a revolutionary paradigm. The goal for the 21st century is no longer simply to extend life, but rather to reverse the aging process itself.

What is aging? The two sides of the same coin

Aging can be defined in two complementary ways. Biologically, it is the progressive deterioration of our bodily functions, a process driven at the molecular level by the accumulation of damage. These include DNA mutations and the appearance of senescent cells, “elderly” cells that stop dividing but remain in tissues, impairing their function. The accumulation of this damage alters tissues and makes us vulnerable to diseases such as cancer, diabetes, and neurodegeneration.

However, the most rigorous definition of aging is statistical: it is the exponential increase in the probability of dying as time passes, due to our increasing fragility in the face of multiple pathologies.

This concept becomes clearer when looking at species that escape this rule, organisms with what is scientifically known as “negligible senescence.” Animals like the Iceland clam ( Arctica islandica ), the Galapagos giant tortoise ( Chelonoidis niger ), or even mammals like the shaved mouse ( Heterocephalus glaber ) do not show an increase in their likelihood of death with age. A 150-year-old tortoise, for example, has the same risk of dying as a 10-year-old.

The scientific revolution of the 21st century: aging can be reversed

The idea that aging is a fixed and unchanging biological process began to crumble in 1993. Biologist Cynthia Kenyon demonstrated that altering a single gene in the worm  C. elegans  could double its lifespan . ^[1]  This milestone proved that aging was a malleable and genetically regulated process, although the possibility of a similar intervention in humans still seemed a very distant goal.

Thirteen years later, in 2006, came the conceptual leap that changed everything. Japanese scientist Shinya Yamanaka discovered that introducing just four transcription factors (OCT4, SOX2, KLF4, and c-MYC) into adult cells  could reverse their “biological clock . ” ^[2]  The cells regressed to a pluripotent state, similar to that of embryonic stem cells. In essence, he showed that cells can be “rejuvenated” if the right genetic program is reactivated.

This discovery, which earned Yamanaka the Nobel Prize in Medicine in 2012, not only revolutionized the understanding of cell regeneration but also redefined the goal of the science of aging. The paradigm shifted: the goal was no longer simply to slow aging, but to seek its reversal. The exploration of this idea represents one of the most exciting frontiers of modern science. Although significant barriers to clinical application remain, the scientific community largely views them as technical challenges that innovation can overcome.

Currently, very different areas of research coexist. 

The discovery of the Yamanaka factors has opened up multiple lines of research into aging, a multifactorial process influenced by genetics, epigenetics, metabolism, and other mechanisms that interact in complex ways. Therefore, several approaches to the fight against aging coexist today. Among them, Harvard professor David Sinclair highlights three particularly promising ones: the elimination of senescent cells, partial epigenetic reprogramming, and the application of artificial intelligence in healthcare. ^[3]

This research boom has been driven by advances in cellular and molecular biology tools, which allow for increasingly precise analysis of the behavior of our cells and their integration into tissues and organs. A prominent example is the development, in 2013, of the first “epigenetic clock” by Steve Horvath, capable of predicting the biological age of  most tissues and organs in the human body with remarkable accuracy. ^[4]   This tool has become an essential resource for evaluating the effectiveness of anti-aging interventions.

 Elimination of senescent cells

As we age, some of our cells enter senescence: they stop their division cycle and begin to secrete inflammatory substances that damage neighboring healthy cells. These senescent cells directly contribute to diseases such as arthritis, fibrosis, and other chronic conditions.

In 2011, a Mayo Clinic team led by James Kirkland presented the first experimental results in mice demonstrating the possibility of selectively eliminating  senescent cells. ^[5]   This was the first direct evidence that their elimination could rejuvenate tissues and delay the onset of aging-related diseases. This finding laid the groundwork for the development of pharmacological compounds called senolytics, capable of eliminating senescent cells without the need to genetically modify the patient, a pharmacological milestone achieved in 2015.

The results in animal models have been impressive, with improvements in physical function and an increase in lifespan of up to 36%. This approach has been one of the first to reach human clinical trials for treating osteoarthritis, pulmonary fibrosis, and age-related frailty. As biogerontologist Judith Campisi summarizes: “If we’re right, and the mouse models are correct, [senolytics] are going to treat a huge range of age-related diseases.” ^[6]

Partial Cell Reprogramming

It’s been proven that aging resides less in our genes (DNA, or  hardware ) and more in our epigenome: the chemical markers attached to DNA that act like  software , telling each cell which genes to turn on or off. Over time, this software accumulates “noise” and errors, causing cells to lose their identity and youthful function.

To address this problem, a strategy is being developed to “reset” this epigenetic software. The technique involves the temporary application of “Yamanaka factors.” The goal is not to completely erase the cell’s identity (which could lead to tumors), but rather to cleanse it of accumulated epigenetic noise to return it to a functionally younger state.

In 2016, Juan Carlos Izpisúa Belmonte’s team at the Salk Institute published  a groundbreaking study. ^[7]  By applying these factors cyclically and for short periods to mice with premature aging (progeria), they managed not only to halt but also partially reverse their deterioration. The treated mice lived 30% longer, showing visibly rejuvenated organs and tissues. This milestone constituted the first conclusive demonstration that the biological age of a complex organism could be reversed.

The potential of this technology has sparked unprecedented interest in private equity. In 2021, Altos Labs was founded with an initial investment of nearly $3 billion, with Amazon founder Jeff Bezos as one of its main investors. The company recruited a true scientific “dream team” that includes, in addition to Izpisúa himself and Steve Horvath, discoverer of the epigenetic clock, four Nobel Prize winners: Shinya Yamanaka, Jennifer Doudna, Frances Arnold, and David Baltimore. The company’s stated goal is ambitious: “to enable people to live healthier lives for longer and reverse diseases in patients of all ages.” ^[8]

Live longer, but above all, live better

The extraordinary advances in aging research over the past two decades have opened a fascinating debate about the limits of human lifespan. At one extreme are futuristic visions such as that of Aubrey de Grey, co-founder of the SENS Research Foundation, who predicts that “the first human being who will live to be 1,000 has already been born” ^[9] . De Grey argues that all seven types of cellular damage that cause aging will be repairable in the near future.

In contrast to this view, the current scientific consensus proposes a more pragmatic and desirable goal: extending healthy life ( healthspan ), not just chronologically. The goal is not to achieve extreme longevity, but rather to compress the period of illness and frailty so that a person can maintain their vitality for as long as possible.

This is the philosophy that Juan Carlos Izpisúa himself summarizes: “The idea behind our research is not that human beings should live 100 or 1,000 more years. If we were able to prolong life without improving the quality of those years, not only would it be morally questionable, but I would also wonder what purpose it would serve.” ^[10]

Manuel Ribes  . Institute of Life Sciences. Bioethics Observatory. Catholic University of Valencia

***

[1]  Kenyon, C., Chang, J., Gensch, E.  et al.  A  C. elegans  mutant that lives twice as long as wild type.  Nature  366, 461–464 (1993).  https://doi.org/10.1038/366461a0

[2]   Kazutoshi Takahashi and Shinya Yamanaka  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors   Cell 126, 663–676, August 25, 2006 DOI 10.1016/j.cell.2006.07.024

[3]  Arkadi Mazin  David Sinclair Hopes Rejuvenation Possible in a Few Decades   Lifespan Research Institute  Mar 22, 2024

[4]   Steve Horvath  DNA methylation age of human tissues and cell types  Genome Biology, 14:R115 2013 http://genomebiology.com//14/10/R115

[5]  Baker, D., Wijshake, T., Tchkonia, T.  et al.  Clearance of p16Ink4a-positive senescent cells delays aging-associated disorders.  Nature  479, 232–236 (2011).  https://doi.org/10.1038/nature10600

[6]  Nicola Bagalà  An Interview with Dr. Judith Campisi  Lifespan Research Institute   Apr 3, 2019

[7]  Ocampo et al., 2016, Cell 167, 1719–1733 December 15, 2016.  http://dx.doi.org/10.1016/j.cell.2016.11.052

[8]   Manuel Ansede “Within two decades we will be able to prevent aging” El País 2022/03/07

[9]  Mike Brown  Why This Aging Expert Thinks First 1,000-Year-Old Person is Already Alive   INVERSE DEC. 1, 2017

[10]  Manuel Ansede “Within two decades we will be able to prevent aging” El País 2022/03/07